Last reviewed · How we verify
NCT06034002
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Phase 1 trial testing INCA033989 in Myeloproliferative Neoplasms in 290 participants. Currently enrolling.
29 October 2028
Quick facts
| Lead sponsor | Incyte Corporation |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 290 |
| Start date | 4 December 2023 |
| Primary completion | 29 October 2028 |
| Estimated completion | 29 October 2028 |
| Sites | 13 locations across United States |
Drugs / interventions tested
- INCA033989 — full drug profile →
- Ruxolitinib (RUXOLITINIB) — full drug profile →
Conditions studied
- Myeloproliferative Neoplasms — all drugs for Myeloproliferative Neoplasms →
Sponsor
Incyte Corporation — full company profile →
Who can join
18 and older, any sex, with Myeloproliferative Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel approaches in myelofibrosis.
Koschmieder S. · · 2024 · cited 7× · PMID 39670187 · DOI 10.1002/hem3.70056 -
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.
Goulart H, Masarova L, Mesa R, Harrison C, et al · · 2024 · cited 7× · PMID 38853641 · DOI 10.1111/bjh.19557 -
JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In-Patient Developments 2024-2025.
Shahid AM, Vainchenker W, Constantinescu SN. · · 2025 · cited 3× · PMID 40619749 · DOI 10.1111/jcmm.70700 -
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
Palandri F, Branzanti F, Morsia E, Dedola A, et al · · 2025 · cited 2× · PMID 39831987 · DOI 10.1007/s00277-025-06204-5 -
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.
Faiz M, Riedemann M, Jutzi JS, Mullally A. · · 2025 · cited 2× · PMID 39775969 · DOI 10.1007/s11899-024-00749-4 -
Evolution of myeloproliferative neoplasms from normal blood stem cells.
Hormoz S, Sankaran VG, Mullally A. · · 2025 · cited 2× · PMID 39633553 · DOI 10.3324/haematol.2023.283951 -
Molecular profiling in MPN: who should have it and why?
Chee A, Mead AJ. · · 2024 · cited 1× · PMID 39644028 · DOI 10.1182/hematology.2024000576 -
Mutant calreticulin-Cancer driver and Achilles' heel for ET?
Reichert M, Psaila B. · · 2026 · PMID 42038747 · DOI 10.1002/hem3.70368
Verify or expand the search:
- PubMed search for NCT06034002
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of INCA033989
Trials testing the same drug.
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
- NCT05936359 — A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye · Phase 1 · recruiting
Other recruiting trials for Myeloproliferative Neoplasms
Currently open trials in the same condition.
- NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
- NCT07008118 — A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
- NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
- NCT06313593 — A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
- NCT05936359 — A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye · Phase 1 · recruiting
Other Incyte Corporation trials
Trials by the same sponsor.
- NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
- NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
- NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
- NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06034002 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06034002.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing